ClinicalTrials.gg
CompletedNCT03523572Updated Jan 27, 2025Results posted

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

A Phase 1 interventional study of Trastuzumab deruxtecan and Nivolumab in Breast Cancer and Urothelial Carcinoma, sponsored by Daiichi Sankyo. Completed at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
36th of 58
86 · median 139
Started
2018
with 5 others
Phase 1
6 of 58
1 open now
Registered
6th of 58
by date
Lead sponsor
9 of 58
Daiichi Sankyo

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 36th largest by enrollment, is one of 6 that started in 2018, is one of 6 in phase 1, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a study of trastuzumab deruxtecan for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.

Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab.

The study will be done in two parts:

  • Part 1 is to identify the recommended dose to use for treatment.
  • Part 2 is to find out how well the combination works, and how safe and tolerable it is.
Read the detailed description

The purpose of this phase 1b (Part 1, Part 2) study is to assess the combination of a test drug (trastuzumab deruxtecan) with nivolumab in participants with HER2-expressing breast and urothelial cancer who had disease progression during or after prior therapies, did not respond to standard therapies, or for whom no standard therapy is available.

The study will be performed in 2 parts.

  • Part 1 is to test different doses of trastuzumab deruxtecan when given along with a fixed dose of nivolumab, and establish the maximum tolerated dose/recommended dose for expansion, when used in combination with nivolumab
  • Part 2 is to assess the efficacy and safety of this dose combination.
03

Conditions studied

  • Breast Cancer
  • Urothelial Carcinoma

Keywords

  • Human epidermal growth factor receptor-2
  • HER2
  • Refractory
  • Metastatic
  • Urothelial cancer
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is the age of majority (adulthood) in their country
  2. Has an Performance Status (ECOG PS) of 0 to 1
  3. Has documented breast cancer or urothelial cancer that is unresectable or , and to or intolerant of existing therapy(ies) known to provide clinical benefit, and as specified in each study cohort
  4. Has an adequate available for the central laboratory to determine eligibility to participate
  5. Has at least 1 per version 1.1
  6. Has cardiac, bone marrow, kidney, liver, blood and clotting test results required per protocol
  7. Has had an adequate before enrollment since previous surgery and other treatment
  8. If reproduction is possible, agrees to use protocol-defined methods of (or completely abstain from heterosexual intercourse) from screening to at least 7 months for females and males after the last dose of study drug
  9. Agrees to avoid harvesting sperm or ova for any reason from screening to at least 7 months for females and males after the last dose of study drug
  10. Has a of at least 3 months

Exclusion criteria

Exclusion Criteria:

  1. Has received prior treatment with nivolumab or trastuzumab deruxtecan
  2. Has medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF) ( classes II-IV). Troponin levels above (ULN) at screening (as defined by the manufacturer) and without any MI-related symptoms should have a cardiologic consultation before enrollment to rule out MI.
  3. Has a interval by Fredericia (QTcF) prolongation to > 470 ms (females) or > 450 ms (males) based on an average of the screening triplicate 12-lead
  4. Has history of non-infectious interstitial lung disease (ILD/pneumonitis) (that required ), has ILD/pneumonitis currently, or it cannot be ruled out by imaging at screening
  5. Has a condition (other than active disease) that requires systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other medications within 14 days of starting study treatment
  6. Is pregnant or breastfeeding, or planning to become pregnant
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Dose Escalation (3.2 mg/kg)

    Participants with HER2-expressing breast cancer who received starting intravenous dose of trastuzumab deruxtecan at 3.2 mg/kg and a fixed intravenous dose of 360mg of nivolumab every 3 weeks (Q3W). Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab was administered on Day 1 of each 21-day cycle. The DLT observation period will be the first 2 cycles.

    Drug: Trastuzumab deruxtecan · Drug: Nivolumab

  • Experimental
    Dose Escalation (5.4 mg/kg)

    Participants with HER2-expressing breast cancer who received starting intravenous dose of trastuzumab deruxtecan at 3.2 mg/kg and a fixed intravenous dose of 360mg of nivolumab every 3 weeks (Q3W). Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab was administered on Day 1 of each 21-day cycle. The DLT observation period will be the first 2 cycles.

    Drug: Trastuzumab deruxtecan · Drug: Nivolumab

  • Experimental
    Dose Expansion - Cohort 1

    Cohort 1: Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) \[as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines\]. These participants received prior ado-trastuzumab emtansine (T-DM1). Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.

    Drug: Trastuzumab deruxtecan · Drug: Nivolumab

  • Experimental
    Dose Expansion - Cohort 2

    Cohort 2: Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive). Participants received the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.

    Drug: Trastuzumab deruxtecan · Drug: Nivolumab

  • Experimental
    Dose Expansion - Cohort 3

    Cohort 3: Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression. Participants received the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.

    Drug: Trastuzumab deruxtecan · Drug: Nivolumab

  • Experimental
    Dose Expansion - Cohort 4

    Cohort 4: Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression. Participants received the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.

    Drug: Trastuzumab deruxtecan · Drug: Nivolumab

Interventions

  • The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.

    Also known as: Enhertu®, T-DXd

  • Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.

    Also known as: Opdivo®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation

    A Dose-Limiting Toxicity (DLT) is defined as any Treatment Emergent Adverse Event not attributable to disease or disease-related processes that occurs during the DLT evaluation period (2 complete cycles during Part 1) and is Grade 3 or above according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Each cycle is 21 days. Low dose was set at 3.2 mg/kg and high dose was set at 5.4 mg/kg.

    Time frame: Cycles 1 and 2 (each cycle is 21 days)

  2. Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

    The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

    Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 2 years 11.5 months (each cycle is 21 days)

Secondary outcomes

  1. Duration of Response (DoR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

    Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

    Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)

  2. Percentage of Participants With Disease Control Rate (DCR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

    Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

    Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)

  3. Progression-Free Survival (PFS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

    Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

    Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)

  4. Time to Response (TTR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

    Time to response (TTR) is defined as the time from the date of first dose of study treatment to the date of the first documented objective response (CR or PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmation of CR/PR was required. TTR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

    Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)

  5. Overall Survival (OS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

    Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

    Time frame: Date of first dose of study drug to the date of death due to any cause, up to 5 years

  6. Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

    The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment (IA) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on IA is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

    Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    A treatment-emergent adverse event (TEAE) was defined as an AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiating the study drug until 47 days after last dose of study drug.

    Time frame: Date of signing the informed consent form up to 100 days after last dose of study drug or start of a new anticancer drug (whichever occurs first), up to 5 years

07

Results

Posted Jan 27, 2025

Participant flow

A total of 86 participants were enrolled and treated at 21 study sites in US and Europe. Final study results are reported for all outcome measures.

Dose Escalation
Participant flow — Dose Escalation
MilestoneDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Started430000
Completed010000
Not completed420000
Withdrew: Progressive disease100000
Withdrew: Clinical progression010000
Withdrew: Adverse event200000
Withdrew: Physician decision110000
Dose Expansion
Participant flow — Dose Expansion
MilestoneDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Started002916304
Completed006140
Not completed002315264
Withdrew: Progressive disease00911152
Withdrew: Clinical progression002220
Withdrew: Adverse event0010152
Withdrew: Withdrawal by subject001100
Withdrew: Physician decision001010
Withdrew: Miscellaneous000030

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation

A Dose-Limiting Toxicity (DLT) is defined as any Treatment Emergent Adverse Event not attributable to disease or disease-related processes that occurs during the DLT evaluation period (2 complete cycles during Part 1) and is Grade 3 or above according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Each cycle is 21 days. Low dose was set at 3.2 mg/kg and high dose was set at 5.4 mg/kg.

Time frame:
Cycles 1 and 2 (each cycle is 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation
ParticipantsDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)
Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation00
PrimaryPercentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

Time frame:
Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 2 years 11.5 months (each cycle is 21 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Percentage of ParticipantsDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer25.0 (NA to NA)65.6 (46.8 to 81.4)50.0 (24.7 to 75.3)36.7 (19.9 to 56.1)50.0 (NA to NA)
SecondaryDuration of Response (DoR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

Time frame:
Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Reported as:
Median · months
Duration of Response (DoR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
monthsDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Independent Central Review—NA (7.9 to NA)5.5 (2.8 to 8.0)13.1 (4.1 to NA)NA (NA to NA)
Investigator Assessment—20.2 (10.4 to NA)5.8 (5.2 to 10.4)8.7 (2.8 to NA)NA (NA to NA)
SecondaryPercentage of Participants With Disease Control Rate (DCR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

Time frame:
Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Control Rate (DCR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Percentage of ParticipantsDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Independent Central Review50 (NA to NA)93.8 (79.2 to 99.2)75.0 (47.6 to 92.7)76.7 (57.7 to 90.1)75.0 (NA to NA)
Investigator Assessment50 (NA to NA)93.8 (79.2 to 99.2)87.5 (61.7 to 98.4)73.3 (54.1 to 87.7)50 (NA to NA)
SecondaryProgression-Free Survival (PFS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

Time frame:
Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Reported as:
Median · months
Progression-Free Survival (PFS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
monthsDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Independent Central Review—11.6 (6.9 to NA)7.0 (2.3 to 10.8)6.9 (2.7 to 14.4)NA (NA to NA)
Investigator Assessment—18.0 (11.0 to NA)7.8 (2.4 to 9.8)5.5 (2.7 to 8.5)NA (NA to NA)
SecondaryTime to Response (TTR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

Time to response (TTR) is defined as the time from the date of first dose of study treatment to the date of the first documented objective response (CR or PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmation of CR/PR was required. TTR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

Time frame:
Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Reported as:
Median · months
Time to Response (TTR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
monthsDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Time to Response (TTR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer1.41 (1.41 to 1.41)1.61 (1.2 to 5.5)3.73 (2.6 to 9.8)1.87 (1.2 to 6.9)3.25 (1.2 to 5.3)
SecondaryOverall Survival (OS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

Time frame:
Date of first dose of study drug to the date of death due to any cause, up to 5 years
Reported as:
Median · months
Overall Survival (OS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
monthsDose Escalation (3.2 kg/mg)Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Overall Survival (OS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial CancerNA (NA to NA)NA (20.8 to NA)19.5 (2.7 to NA)11.0 (7.2 to NA)NA (NA to NA)
SecondaryPercentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer

The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment (IA) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on IA is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).

Time frame:
Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Percentage of ParticipantsDose Escalation (3.2 kg/mg)Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer25 (NA to NA)71.9 (53.3 to 86.3)43.8 (19.8 to 70.1)40.0 (22.7 to 59.4)25.0 (NA to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

A treatment-emergent adverse event (TEAE) was defined as an AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiating the study drug until 47 days after last dose of study drug.

Time frame:
Date of signing the informed consent form up to 100 days after last dose of study drug or start of a new anticancer drug (whichever occurs first), up to 5 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsDose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC
Number of Participants With Treatment Emergent Adverse Events (TEAEs)432916304

Adverse events

Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 100 days after last dose of the study drug, up 5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation (3.4 mg/kg)2/4 (50%)3/4 (75%)4/4 (100%)
Dose Escalation (5.4 mg/kg)1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Dose Expansion Cohort 1: HER2 Positive BC7/29 (24.1%)12/29 (41.4%)29/29 (100%)
Dose Expansion Cohort 2: HER2 Low BC8/16 (50%)4/16 (25%)16/16 (100%)
Dose Expansion Cohort 3: HER2 High Expressing (IHC 2+/3+) UC17/30 (56.7%)17/30 (56.7%)30/30 (100%)
Dose Expansion Cohort 4: HER2 Low Expressing (IHC 1+) UC0/4 (0%)3/4 (75%)4/4 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventDose Escalation (3.4 mg/kg)Dose Escalation (5.4 mg/kg)Dose Expansion Cohort 1: HER2 Positive BCDose Expansion Cohort 2: HER2 Low BCDose Expansion Cohort 3: HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4: HER2 Low Expressing (IHC 1+) UC
Disease ProgressionGeneral disorders0/41/31/291/162/300/4
PneumothoraxInjury, poisoning and procedural complications0/41/30/290/160/300/4
PneumonitisRespiratory, thoracic and mediastinal disorders1/40/31/290/162/301/4
PneumoniaInfections and infestations1/40/31/290/161/300/4
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/30/290/160/301/4
PyelonephritisInfections and infestations0/40/30/290/160/301/4
ThrombocytopeniaBlood and lymphatic system disorders0/40/30/290/160/301/4
Abdominal painGastrointestinal disorders1/40/30/290/160/300/4
Bile duct obstructionHepatobiliary disorders1/40/30/290/160/300/4
DehydrationMetabolism and nutrition disorders1/40/30/290/160/300/4
Most frequent other events
Showing 10 of 178
Most frequent other events
EventDose Escalation (3.4 mg/kg)Dose Escalation (5.4 mg/kg)Dose Expansion Cohort 1: HER2 Positive BCDose Expansion Cohort 2: HER2 Low BCDose Expansion Cohort 3: HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4: HER2 Low Expressing (IHC 1+) UC
FatigueGeneral disorders1/43/314/296/1616/302/4
NauseaGastrointestinal disorders2/41/316/2910/1622/303/4
Oedema PeripheralGeneral disorders3/42/36/292/165/300/4
Dry MouthGastrointestinal disorders3/40/31/292/162/300/4
DiarrhoeaGastrointestinal disorders0/42/311/296/1613/300/4
AlopeciaSkin and subcutaneous tissue disorders0/42/313/296/162/300/4
VomitingGastrointestinal disorders1/41/39/298/1614/301/4
AnaemiaBlood and lymphatic system disorders1/40/311/298/168/302/4
PneumonitisRespiratory, thoracic and mediastinal disorders1/40/34/291/164/302/4
HypokalaemiaMetabolism and nutrition disorders2/40/36/290/163/301/4

Baseline characteristics

Baseline characteristics were assessed using the Full Analysis Set.

Age, Categorical
Age, Categorical(Participants)Dose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UCTotal
<=18 years0000000
Between 18 and 65 years2124168253
>=65 years225022233
Age, Continuous
Age, Continuous(years)Dose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UCTotal
Mean60.73 ± 10.97863.99 ± 16.99556.37 ± 9.79948.11 ± 8.78169.29 ± 10.35259.71 ± 13.30859.48 ± 12.672
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UCTotal
Female43291627382
Male0000314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UCTotal
American Indian or Alaska Native0000000
Asian0011002
Native Hawaiian or Other Pacific Islander0000000
Black or African American1050006
White33231428475
More than one race0000202
Unknown or Not Reported0001001
Region of Enrollment
Region of Enrollment(participants)Dose Escalation (3.2 mg/kg)Dose Escalation (5.4 mg/kg)Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BCDose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BCDose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UCDose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UCTotal
Belgium0020327
United States431777038
Italy00317112
United Kingdom0031105
France0000202
Germany0000415
Spain00476017
08

Study locations

29 sites
  • UCLA - Medical Center
    Santa Monica, California 90404, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Levine Cancer Institute Carolinas Healthcare System
    Charlotte, North Carolina 28204, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Tennessee Oncology - Sara Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • University of Washington Medical Center
    Seattle, Washington 98109, United States
  • AZ Groeninge
    Kortrijk, West-Vlaanderen 8500, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • GZA Hospital Campus Sint-Augustinus
    Wilrijk, 2610, Belgium
  • Institut de Cancerologie de L'Ouest
    Angers, 49055, France
  • Centre Georges Francois Leclerc
    Dijon, 21079, France
  • ICO Rene Gauducheau
    Saint-Herblain, 44805, France
  • Charite Campus Benjamin Franklin
    Berlin, Brandenburg 12200, Germany
  • University Hospital Frankfurt
    Frankfurt, Hessen 60590, Germany
  • University Cancer Center
    Dresden, Sachsen 01307, Germany
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, 20133, Italy
  • Azienda Ospedaliera Universitaria Senese U.O.C. Immunoterapia Oncologica
    Siena, 53100, Italy
  • Hospital Gregorio Maranon Madrid Spain
    Madrid, 28007, Spain
  • MD Anderson Cancer Center Madrid
    Madrid, 28033, Spain
  • Hospital Universitario Ramon y Cajal Madrid
    Madrid, 28034, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • START Madrid CIOCC
    Madrid, 28050, Spain
  • Sarah Cannon Research Institute UK
    London, England W1G6AD, United Kingdom
  • Royal Marsden Hospital (Surrey)
    London Borough of Sutton, SM25PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jul 2021, 35 months.

Results were first posted in Jan 2025, 3 years 6 months after primary completion.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 35 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2018
First posted
May 14, 2018
StartActual
Aug 2, 2018
Primary completionActual
Jul 22, 2021
CompletionActual
Sep 12, 2023
Results first posted
Jan 27, 2025
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03523572
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 14, 2018
Start date
Aug 2, 2018
Primary completion
Jul 22, 2021
Completion
Sep 12, 2023
Results posted
Jan 27, 2025
Last update
Jan 27, 2025

Study contacts

Global Team Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion